CEO's Severance Package Significantly Increased in Amended Agreement
ALLR has more than doubled off its 52-week low of $0.769.
Summary
Allarity Therapeutics amended its CEO's management agreement, increasing his severance to 12 months of salary, a notable financial commitment for the company.
Key Events · Executive and Board Changes · ALLR
-
CEO Compensation Agreement Amended
The company entered into an Amended and Restated Management Services Agreement with CEO Thomas H. Jensen, effective June 1, 2026, replacing the original agreement from June 1, 2024.
-
Severance Package Increased
The CEO's severance entitlement upon termination for convenience by the company or for good reason by the consultant was increased to 12 months of the monthly fee, in addition to accrued payments. This is an increase from the prior terms, which offered only accrued payments or accrued payments plus nine months, respectively.
-
Base Salary Details
The annual base salary for 2026 is set at SEK 6,000,000 and US$163,043, payable 80% in Swedish Krona and 20% in U.S. dollars.
-
Signing Bonus Eliminated
The one-time $100,000 signing bonus provided under the original agreement was eliminated in the amended terms.
Analysis · ALLR · Life Sciences
Allarity Therapeutics has amended its management services agreement with CEO Thomas H. Jensen, substantially increasing his severance package. If terminated for convenience by the company or for good reason by the consultant, the CEO is now entitled to 12 months of his monthly fee, in addition to accrued payments. This represents a significant financial obligation for the company, equivalent to approximately 2.7% of its current market capitalization, and could impact future operational flexibility.
At the time of this filing, ALLR was trading at $1.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.9M. The 52-week trading range was $0.77 to $2.35. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.